Bio-pharmaceuticals

Next-generation antimicrobial compounds and combinations designed to overcome multi-drug resistant (MDR) bacterial infections and address the global AMR crisis.

Targeted oncology therapies utilizing monoclonal antibodies to deliver highly potent cytotoxic payloads directly to cancer cells, minimizing systemic toxicity.

Utilizing naturally occurring or precision-engineered bacterial viruses to selectively target and eradicate specific pathogenic bacterial strains without harming the microbiome.

Physical-containment infrastructure — biological safety cabinets, HEPA filtration, autoclave sterilization and BSL-1 to BSL-4 containment — that protects personnel, product and environment in every biotechnology laboratory, governed by NSF/ANSI 49 and EN 12469.

The commercial gene-synthesis service and biofoundry layer of synthetic biology — turning digital DNA designs into delivered genes, clones and strain builds through phosphoramidite and emerging enzymatic synthesis, governed by pathogen-sequence biosecurity screening.

Precision delivery of functional genetic material via engineered vectors to treat inherited diseases and severe genetic disorders at their root cause.

Regulated door-to-door transport of Category A and B infectious substances under IATA Packing Instructions 602/650, using triple packaging, biosafety couriers and chain-of-custody tracking.

One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.

Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel disease and immuno-oncology support.

Automated mini- and micro-bioreactors (1-250 mL) running 24-48 cultures in parallel that map a bioprocess Design Space in days rather than months — the high-throughput on-ramp to cell-line, strain and upstream-process development, led by the German ambr, BioLector and DASbox platforms.

Authenticated microbial type strains and WHO biological reference materials — the calibrated living standards underpinning pharmaceutical QC, diagnostics, taxonomy and patent deposit, held by a global network of biological resource centers from the century-old ATCC to NIBSC.

Gamma-irradiated single-use bag bioreactors in the 50-2000 L stirred-tank class — Sartorius Biostat STR, Cytiva Xcellerex XDR, Thermo Fisher HyPerforma, Merck Mobius — that replaced stainless steel for clinical and commercial mAb, vaccine and cell-and-gene-therapy manufacturing, cutting facility build-out from years to weeks and underpinning the CDMO economy.